1614

CASE PC/4-32771A



### FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731066791 US Express Mail Label Number December 13, 2005 Date of Deposit

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

FARIBORZ FIROODZNIA

INTERNATIONAL APPLICATION NO: EP03/12851

FILED: 17 NOVEMBER 2003

U.S. APPLICATION NO: 10/534,631 35 USC §371 DATE: 11 MAY 2005

FOR: IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR

TREATING ALDOSTERONE MEDIATED DISEASES

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (617) 871-3096 CZ/mrw

Date: December 13, 2005

Attorney for Applicant

Reg. No. 53,827

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. PC/4-32771A APPLICATION NO. 10/534,631 APPLICANT Fariborz Firoodznia FILING DATE MAY 11, 2005

Group 1614

DEC 1 3 2005

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,588,732	5/13/86	Browne			
	AB	4,617,307	10/14/86	Browne			
	AC	6,037,349	3/14/00	Sombroek et al.			
	AD	US 4,889,861	11/2002	Novartis			
	AE	US 4, 617,307	11/2002	Novratis			
	AF	US 5, 529, 992	11/2002	University of Missouri			
	AG	US 6,150, 347	11/2002	University of Missouri			
	АН						
	Al						
	AJ						
	AK						
	AL						

#### **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
AM	JP 09071586	11/2002	Yamanouchi Pharmaceutical				
AN	WO 01/27107	11/2002	BMS				
AO							
AP							
AQ							

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AT	
AS	
AR Aroma	ne, L.J. et al., "Fadrozole Hydrochloride: A Potent, Selective, Nonsteroidal Inhibitor of atase for the Treatment of Estrogen-Dependent Disease," J. Med. Chem. Vol. 34, 1991, pp. 36, (1991)

EXAMINER

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.